Abstract: Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) frequently metastasizes to the central nervous system (CNS), presenting a significant clinical challenge due to the limited blood-brain barrier (BBB) penetration of early-generation tyrosine kinase inhibitors (TKIs). Lazertinib (YH25448) is a highly selective, third-generation, irreversible EGFR-TKI specifically designed to overcome these limitations. It demonstrates potent activity against both sensitizing EGFR mutations and the T790M resistance mutation while sparing wild-type EGFR. Structurally optimized with a unique pyrazole group, lazertinib achieves excellent CNS penetrance, exhibiting high intracranial objective response rates and prolonged progression-free survival in patients with brain metastases. Recent landmark trials, such as MARIPOSA, have highlighted the superior efficacy of lazertinib when combined with the bispecific antibody amivantamab, significantly improving CNS-specific outcomes compared to osimertinib monotherapy. This review synthesizes the pharmacological activity, molecular mechanisms, structure-activity relationships, current limitations, and future perspectives of lazertinib in the management of EGFR-mutated NSCLC with CNS metastases.
1. Introduction
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases [5]. A significant proportion of NSCLC patients harbor activating mutations in the epidermal growth factor receptor (EGFR), most commonly exon 19 deletions (Ex19del) and exon 21 L858R point mutations [2][5]. While first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) revolutionized the treatment landscape, their long-term efficacy is inevitably hindered by acquired resistance, predominantly driven by the T790M gatekeeper mutation [2][6].
Furthermore, central nervous system (CNS) metastasis is a frequent and devastating complication in this patient population. Approximately 30% to 50% of patients with EGFR-mutated advanced NSCLC develop CNS metastases within five years of diagnosis [1][6]. The management of these metastases is particularly challenging because first- and second-generation EGFR-TKIs, as well as traditional chemotherapy, exhibit limited ability to cross the blood-brain barrier (BBB), allowing the CNS to act as a sanctuary site for tumor progression [5]. To address the dual challenges of T790M-mediated resistance and inadequate CNS penetrance, third-generation EGFR-TKIs were developed. Lazertinib (YH25448) is a highly brain-penetrant, third-generation EGFR-TKI that has demonstrated exceptional clinical efficacy, particularly in preventing and treating intracranial lesions, thereby reshaping the therapeutic sequencing for EGFR-mutated NSCLC [2][10].
2. Pharmacological Activity
Lazertinib exhibits a highly favorable pharmacokinetic and pharmacodynamic profile, particularly regarding its ability to penetrate the CNS. Preclinical models demonstrated that lazertinib has high blood-brain permeability, achieving intracranial tumor-to-plasma and intracranial tumor-to-brain area under the curve (AUC) ratios of 7.0 and 7.9, respectively [2]. The unbound brain-to-plasma partition coefficient (Kpuu) for lazertinib is 0.29, which is superior to early-generation TKIs and comparable to or slightly better than osimertinib (0.21) [3]. In murine brain metastasis models, lazertinib was significantly more effective than equimolar concentrations of osimertinib in inducing tumor regression [2][13].
Clinically, lazertinib has shown robust intracranial efficacy. In patients with measurable brain lesions, lazertinib monotherapy achieved an intracranial objective response rate (ORR) of up to 94.4% and an intracranial progression-free survival (PFS) ranging from 16.4 to 28.2 months [3]. The therapeutic potential of lazertinib is further amplified when used in combination regimens. The phase III MARIPOSA trial evaluated the combination of lazertinib and the EGFR-MET bispecific antibody amivantamab as a first-line treatment. This combination yielded a median intracranial PFS of 24.9 months compared to 22.2 months with osimertinib monotherapy, alongside a CNS ORR of 77% [9][12]. These findings underscore lazertinib's potent pharmacological activity in controlling CNS disease, delaying the need for local therapies like whole-brain radiation, and preserving neurocognitive function [1].
3. Molecular Mechanism of Action
Lazertinib is an irreversible, mutant-selective EGFR-TKI. It exerts its mechanism of action by selectively binding to the ATP-binding pocket of the EGFR kinase domain. It is highly potent against both single activating mutations (Ex19del, L858R) and double mutations containing the T790M resistance alteration (Ex19del/T790M and L858R/T790M) [2]. By covalently binding to the C797 residue within the ATP-binding site, lazertinib irreversibly inhibits the receptor's tyrosine kinase activity [8].
This inhibition effectively blocks downstream EGFR signaling pathways, including the phosphorylation of EGFR, AKT, and ERK, which are critical for tumor cell proliferation and survival [2]. Consequently, lazertinib induces apoptosis in EGFR-mutant lung cancer cells, evidenced by an increase in cleaved Bim-EL protein and the activation of caspase 3/7 [2]. Crucially, lazertinib was designed to be highly selective for mutant EGFR while sparing wild-type (WT) EGFR. In vitro studies indicate that lazertinib exhibits less activity against WT EGFR than osimertinib, which contributes to a wider therapeutic window and potentially fewer WT EGFR-related toxicities, such as severe skin rash and diarrhea, when used as a monotherapy [2][8].
4. Structure-Activity Relationship (SAR)
The superior medicinal chemistry profile of lazertinib, particularly its T790M selectivity and CNS penetrance, is deeply rooted in its unique structural design. While it shares the irreversible C797-targeting acrylamide warhead common to other third-generation TKIs, lazertinib differs significantly from osimertinib in its core structure. Specifically, lazertinib replaces the indole ring found on the pyrimidine ring of osimertinib with a 4-phenyl-3-dimethylaminomethyl-1-pyrazole group, and it substitutes the dimethylaminoethyl-N-methyl chain at the 2-position of the phenyl ring with a morpholine group [3].
The structural basis for lazertinib's selectivity against the T790M gatekeeper mutation is facilitated by this substituted pyrazole moiety. The pyrazole group is strategically substituted with a hydrophobic phenyl ring and a hydrophilic, hydrogen-bond-donating amine. This specific combination weakens the drug's binding affinity to WT EGFR while maintaining potent van der Waals and hydrogen-bonding interactions with the L858R and T790M mutant kinase domains [8]. Furthermore, these structural modifications minimize the impact of efflux transporters like P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) at the blood-brain barrier, enabling the high Kpuu values and excellent CNS exposure observed in preclinical and clinical settings [3].
5. Current Limitations
Despite its remarkable efficacy, the clinical utility of lazertinib is constrained by acquired resistance and toxicity, particularly in combination regimens. Like other third-generation TKIs, lazertinib is vulnerable to the emergence of tertiary EGFR mutations. The most prominent on-target resistance mechanism is the EGFR C797S mutation, which substitutes a serine for the cysteine residue at position 797, thereby preventing lazertinib from forming its critical covalent bond and rendering the drug ineffective [6][8][13]. Off-target resistance mechanisms are also prevalent, including MET amplification, PIK3CA alterations, BRAF V600E mutations, and small-cell transformation [2][6].
Toxicity presents another significant limitation, especially when lazertinib is utilized in combination therapies to delay resistance. In the MARIPOSA trial, the combination of lazertinib and amivantamab resulted in 75% of patients experiencing grade 3 or higher treatment-related adverse events (TRAEs), compared to 43% in the osimertinib monotherapy arm [1][6]. Common severe adverse events included venous thromboembolism, paronychia, rash, and infusion-related reactions [6]. This heightened toxicity profile necessitates careful patient selection, as the regimen may not be suitable for patients with significant comorbidities or a poor performance status [1].
6. Future Perspectives
The future of lazertinib in treating EGFR-mutated NSCLC, particularly with CNS involvement, lies in optimizing combination strategies and overcoming resistance. The FDA approval of lazertinib in combination with amivantamab represents a paradigm shift, offering a "one-two punch" that simultaneously targets EGFR and MET pathways, thereby suppressing the emergence of MET-driven resistance and improving progression-free survival [6][8]. Ongoing trials, such as PALOMA-3, are investigating subcutaneous formulations of amivantamab combined with lazertinib to reduce infusion-related reactions and improve patient convenience [8].
To address the inevitable C797S resistance mutation, the development of fourth-generation, reversible, ATP-competitive or allosteric EGFR inhibitors is a critical area of ongoing research [6][8]. Furthermore, the integration of circulating tumor DNA (ctDNA) monitoring will likely play a pivotal role in guiding treatment sequencing. Early clearance of ctDNA has been correlated with longer PFS, suggesting that liquid biopsies could be used to dynamically tailor lazertinib-based therapies, escalating to combinations or novel agents at the earliest molecular signs of resistance before clinical CNS progression occurs [6][10].
